Network pharmacology-based strategy for predicting therapy targets of Ecliptae Herba on breast cancer

被引:13
|
作者
Li, Hui [1 ,2 ,3 ]
Shi, Wei [1 ,2 ,3 ]
Shen, Tingming [4 ]
Hui, Siwen [2 ,3 ]
Hou, Manting [2 ,3 ]
Wei, Ziying [1 ,2 ,3 ]
Qin, Shuanglin [5 ]
Bai, Zhaofang [2 ,3 ]
Cao, Junling [1 ,6 ]
机构
[1] Beijing Univ Chinese Med, Sch Chinese Mat Med, Beijing 102488, Peoples R China
[2] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 5, Dept Hepatol, Beijing, Peoples R China
[3] Chinese Peoples Liberat Army Gen Hosp, China Mil Inst Chinese Mat, Med Ctr 5, Beijing, Peoples R China
[4] Ningde Hosp Tradit Chinese Med, Ningde, Peoples R China
[5] Hubei Univ Sci & Technol, Xianning Med Coll, Sch Pharm, Xianning, Peoples R China
[6] Beijing Univ Chinese Med, Dongzhimen Hosp, Luoyang Branch, Beijing, Peoples R China
基金
中国国家自然科学基金; 中国博士后科学基金;
关键词
breast cancer; Ecliptae Herba; molecular docking; network pharmacology; TGF-beta; 1; MESENCHYMAL TRANSITION; CELL-PROLIFERATION; STEM-CELLS; TGF-BETA; METASTASIS; RESOURCE; EXTRACT;
D O I
10.1097/MD.0000000000035384
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Breast cancer is a prevalent malignancy affecting women globally, characterized by significant morbidity and mortality rates. Ecliptae Herba is a traditional herbal medicine commonly used in clinical practice, has recently been found to possess antitumor properties. In order to explore the underlying material basis and molecular mechanisms responsible for the anti-breast cancer effects of Ecliptae Herba, we used network pharmacology and experimental verification. UPLC-MS/MS was utilized to identify compounds present in Ecliptae Herba. The active components of Ecliptae Herba and its breast cancer targets were screened using public databases. Hub genes were identified using the STRING and Metascape database. The R software was utilized for visual analysis of GO and KEGG pathways. The affinity of the hub targets for the active ingredients was assessed by molecular docking analysis, which was verified by experimental assessment. A total of 178 targets were obtained from the 10 active components of Ecliptae Herba, while 3431 targets associated with breast cancer were screened. There were 144 intersecting targets between the components and the disease. Targets with a higher degree, namely EGFR and TGFB1, were identified through the hub subnetwork of PPI. GO and KEGG analyses revealed that Ecliptae Herba plays an important role in multiple cancer therapeutic mechanisms. Moreover, molecular docking results showed that the core components had good binding affinity with key targets. Finally, it was confirmed that TGF-beta 1 might be a potential crucial target of Ecliptae Herba in the treatment of breast cancer by cytological experiments, and the TGF-beta 1/Smad signaling pathway might be an important pathway for Ecliptae Herba to exert its therapeutic effects. This study elucidated the active ingredients, key targets, and molecular mechanisms of Ecliptae Herba in the treatment of breast cancer, providing a scientific foundation and therapeutic mechanism for the prevention and treatment of breast cancer with Traditional Chinese medicine.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Network pharmacology-based strategy for predicting therapy targets of Sanqi and Huangjing in diabetes mellitus
    Cui, Xiao-Yan
    Wu, Xiao
    Lu, Dan
    Wang, Dan
    WORLD JOURNAL OF CLINICAL CASES, 2022, 10 (20) : 6900 - 6914
  • [2] Network pharmacology-based strategy for predicting therapy targets of Tripterygium wilfordii on acute myeloid leukemia
    Fang, Tingting
    Liu, Lanqin
    Liu, Wenjun
    MEDICINE, 2020, 99 (50) : E23546
  • [3] Network Pharmacology-Based Approach to Investigate the Molecular Targets of Sinomenine for Treating Breast Cancer
    Li, Xiao-Mei
    Li, Mao-Ting
    Jiang, Ni
    Si, Ya-Chen
    Zhu, Meng-Mei
    Wu, Qiao-Yuan
    Shi, Dong-Chen
    Shi, Hui
    Luo, Qing
    Yu, Bing
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 1189 - 1204
  • [4] Network Pharmacology-Based Strategy to Investigate the Anti-Breast Cancer Mechanisms of Spatholobus suberectus Dunn
    Fang, Bo
    Yoo, Guijae
    Lee, Phil Jun
    Qiu, Yinda
    Lee, Sung Hoon
    Lee, Ji Shin
    Yoo, Hee Min
    Cho, Namki
    NATURAL PRODUCT COMMUNICATIONS, 2022, 17 (02)
  • [5] A network pharmacology-based strategy for predicting anti-inflammatory targets of ephedra in treating asthma
    Huang, Xiu-Fang
    Cheng, Wen-Bin
    Jiang, Yong
    Liu, Qiong
    Liu, Xiao-Hong
    Xu, Wei-Fang
    Huang, Hui-Ting
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 83
  • [6] Network pharmacology-based strategy for predicting active ingredients and potential targets of Yangxinshi tablet for treating heart failure
    Chen, Langdong
    Cao, Yan
    Zhang, Hai
    Lv, Diya
    Zhao, Yahong
    Liu, Yanjun
    Ye, Guan
    Chai, Yifeng
    JOURNAL OF ETHNOPHARMACOLOGY, 2018, 219 : 359 - 368
  • [7] Network pharmacology-based strategy to reveal the mechanism of pinocembrin against ovarian cancer
    Wang, Guanghui
    Cheng, Jianxiang
    Yao, Meizhen
    Li, Jing
    Chen, Ting
    Zhang, Jia
    Du, Wensheng
    Chen, Youguo
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2024,
  • [8] Network pharmacology-based approach to investigate the mechanisms of Shenqi Fuzheng injection in the treatment of breast cancer
    Liu, Shuyu
    Wu, Jiarui
    Zhu, Yingli
    Zhou, Wei
    Liu, Xinkui
    Fu, Changgeng
    Ding, Zhiguo
    Xu, Lishan
    Zhang, Ying
    Meng, Ziqi
    Ni, Mengwei
    Jia, Shanshan
    Zhang, Jingyuan
    Guo, Siyu
    EUROPEAN JOURNAL OF INTEGRATIVE MEDICINE, 2020, 34
  • [9] Network pharmacology-based approach to investigate the molecular targets of essential oil obtained from lavender for treating breast cancer
    Maitisha, Guzhalinuer
    Zhou, Junhao
    Zhao, Yan
    Han, Shuxia
    Zhao, Youyun
    Abliz, Ablikim
    Liu, Guangzhong
    HELIYON, 2023, 9 (11)
  • [10] A Network Pharmacology-Based Strategy For Predicting Active Ingredients And Potential Targets Of LiuWei DiHuang Pill In Treating Type 2 Diabetes Mellitus
    He, Dan
    Huang, Jian-Hua
    Zhang, Zhe-Yu
    Du, Qing
    Peng, Wei-Jun
    Yu, Rong
    Zhang, Si-Fang
    Zhang, Shui-Han
    Qin, Yu-Hui
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2019, 13 : 3989 - 4005